Jefferies Starts Pieris Pharmaceuticals (PIRS) at Buy

Jefferies initiates coverage on Pieris Pharmaceuticals (NASDAQ: PIRS) with a Buy rating and a price target of $12.00.

Analyst Biren Amin comments "PIRS should see momentum in H2'18 on first-in-human data from its lead assets PRS-343 and PRS-060 in immuno-oncology and asthma, respectively. The co has a robust discovery platform centered on Anticalin proteins, which mgmt has leveraged to ink multiple high-profile partnerships. As the pipeline matures, we expect an influx of clinical-stage assets to drive value over the next several years."

For an analyst ratings summary and ratings history on Pieris Pharmaceuticals click here. For more ratings news on Pieris Pharmaceuticals click here.

Shares of Pieris Pharmaceuticals closed at $6.81 Friday.

You May Also Be Interested In

• Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
• Visa (V) PT Raised to $412 at Baird
• Strategy (MSTR) PT Lowered to $213 at Mizuho